MeSH D046152 - gastrointestinal stromal tumors
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Sunitinib | Sunitinib |  | 2021-11-30 |  |  |
| Imatinib | Imatinib Teva B.V |  | 2017-11-15 |  |  | |
| Mylan | Sunitinib | Sunitinib |  | 2021-12-06 |  |  |
| Novartis | Imatinib | Glivec |  | 2001-11-07 |  |  |
| Bayer | Regorafenib | Stivarga | 2022-06-28 | 2012-09-27 |  |  |
| Pfizer | Sunitinib | Sutent |  | 2006-07-19 | $180 M | Y2023 |
| Dr Reddys Laboratories | Sunitinib | Sunitinib |  | 2022-04-11 |  |  |
| Sun Pharmaceutical Industries | Sunitinib | Sunitinib |  | 2021-08-16 |  |  |
| Accord Healthcare | Sunitinib | Sunitinib Accord |  | 2021-02-11 |  |  |
| CP Pharmaceuticals International CV | Sunitinib | Sutent |  | 2006-01-26 |  |  |
| Blueprint Medicines | Avapritinib | Ayvakit | 2034-10-15 | 2020-01-09 | $204.207 M | Y2023 |
| Avapritinib | Ayvakyt |  | 2020-09-24 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
64%36/56
Phase 2
12%9/75
Phase 3
50%11/22
Approved: 6Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use